Putting Iatrogenic Risk in Perspective: Basal Cell Cancer in PUVA Patients and Australians  by Stern, Robert S.
protein, hsp27, with keratins and proteins of
the cornified cell envelope. Br J Dermatol
147:13–9
McNamara CR, Mandel-Brehm J, Bautista DM,
Siemens J, Deranian KL, Zhao M et al.
(2007) TRPA1 mediates formalin-induced
pain. Proc Natl Acad Sci USA 104:13525–30
Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J,
Hricik TR et al. (2003) ANKTM1, a TRP-like
channel expressed in nociceptive neurons, is
activated by cold temperatures. Cell 112:819–29
Trautinger F, Kindas-Mu¨gge I, Dekrout B, Knobler
RM, Metze D (1995) Expression of the 27-
kDa heat shock protein in human epidermis
and in epidermal neoplasms: an immunohis-
tological study. Br J Dermatol 133:194–202
Trevisani M, Siemens J, Materazzi S, Bautista
DM, Nassini R, Campi B et al. (2007)
4-Hydroxynonenal, an endogenous alde-
hyde, causes pain and neurogenic inflamma-
tion through activation of the irritant
receptor TRPA1. Proc Natl Acad Sci USA
104:13519–24
Werkheiser JL, Rawls SM, Cowan A (2006) Icilin
evokes a dose- and time-dependent increase
in glutamate within the dorsal striatum of
rats. Amino Acids 30:307–9
Putting Iatrogenic Risk in Perspective: Basal Cell Cancer
in PUVA Patients and Australians
Journal of Investigative Dermatology (2009) 129, 2315–2316; doi:10.1038/jid.2009.36; published online 5 March 2009
TO THE EDITOR
Owing to the lack of comparable
population-based incidence data, a
clinical perspective for assessing basal
cell cancer (BCC) incidence in patients
undergoing potentially carcinogenic
therapies such as psoralens plus UVA
(PUVA) has been largely lacking
(Nijsten and Stern, 2003). The recent
prospective cohort study of BCC inci-
dence in a subtropical Australian po-
pulation provides a clinical, population
context for assessing the BCC risk in
North American PUVA-treated patients
(Richmond-Sinclair et al., 2008). These
data provide additional evidence that
exposure to cutaneous carcinogens in
younger persons results in greater in-
creases of the risk of BCC than compar-
able exposure in older persons
(Gallagher et al, 1995).
I used methods comparable with
those in Richmond-Sinclair’s study to
quantify histologically diagnosed BCC
incidence in the PUVA cohort during a
10-year period (January 1990 to 31
December 1999). Of 1,380 patients
originally enrolled, 1,021 were still
participating in 1990, 14 years after
first exposure to PUVA. A total of 692
(67%) patients were followed for the
entire decade. Of the remaining, 254
had died and 88 were lost to follow-up.
Complete data (up to death) were
available for 92%.
The PUVA cohort was older than the
Nambour cohort (43 vs 24%X60 years,
w2 Po0.001); a higher proportion were
males (64 vs 56%, w2 Po0.001); fewer
patients were fair-skinned (30% skin
types 1 and 2 vs 55% fair-complected
in the Nambour cohort (w2 Po0.001)).
At enrollment, only 10% of the PUVA
cohort lived in subtropical areas com-
parable with that of the Nambour cohort
(below 301 latitude), and most (72%)
lived at or above 401 North latitude.
Although older, the PUVA cohort had a
lower percentage of patients with a
history of BCC before the decade studied
(11 vs 18%, w2 Po0.001).
The age-adjusted incidence of both
cohorts of persons developing one or
more BCCs in a decade was nearly
identical (Table 1). PUVA patients who
Table 1. Age-specific incidence rates of BCC (per 100,000 person-years)
1990–1999 for PUVA cohort and IRR with 95% CI compared with those
for Queensland (Australia)1
PUVA cohort
PUVA compared with
Nambour2
Total
patients
Patient-
years Incidence 95% CI IRR 95% CI
Men, age in years
20–39 5 229 2,183 703–4,588 2.17 0.63–7.50
40–59 53 2,306 2,298 1,721–3,006 1.29 0.87–1.91
60+ 90 2,733 3,293 2,648–4,048 0.83 0.63–1.11
Weighted average3 148 5,268 2,425 2,027–2,889 1.35 1.04–1.75
Women, age in years
20–39 7 444 1,577 631–3,248 4.24 0.88–20.42
40–59 23 1,599 1,484 941–2,228 0.86 0.53–1.38
60+ 24 1,253 1,915 802–1,864 0.71 0.45–1.11
Weighted average3 54 3,247 1,606 1,196–2,100 1.26 0.90–1.78
Total 202 9,515 1,892 1,625–2,189 1.32 1.07–1.62
BCC, basal cell cancer; 95% CI, 95% confidence interval; IRR, incidence rate ratio; PUVA, psoralens
plus UVA.
1Richmond-Sinclair et al. (2008).
2IRR of the PUVA cohort compared with that of Queensland (Richmond-Sinclair et al., 2008).
3Age standardized to the world population (Ahmad et al., 2001).
Abbreviations: BCC, basal cell carcinoma; PUVA, psoralens plus UVA
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started PUVA treatment by the age of
25 years and were o40 years in the
1990s (mean age starting PUVA¼19
years) had a significantly higher risk of
BCC than Nambour patients of compar-
able age (IRR (incidence rate ration)¼
2.64, 95% CI (95% confidence
interval)¼ 1.04–6.70).
When each tumor is counted, the
incidence of tumors was far higher in
the PUVA cohort than in the Nambour
cohort (age-adjusted incidence 239 vs
51 per 1,000 patient-years, Po0.001).
The incidence of BCC (tumor counts)
was significantly higher in patients with
more than 200 PUVA treatments than
those with fewer treatments (IRR¼ 3.1,
95% CI¼ 2.74–3.54).
Table 2 provides the anatomic dis-
tribution of tumors in both cohorts. The
incidence of BCC on the trunk and
lower extremities was more than six
times higher for PUVA patients than for
Australians.
In contrast to the far lower incidence
of BCC in the United States’ general
population, North American patients
who use PUVA and live in temperate
climates have at least as high a risk of
developing at least one BCC as seen in
a fairer-skinned population living in a
subtropical Australia. The greatest in-
crease in risk was seen among those
who started PUVA treatment before age
25 years. The average number of
tumors per patient who developed at
least one BCC was about three times
higher for PUVA patients than for
Australians (Tables 1 and 2). Earlier
reports suggest that the increase in BCC
among Australians is nearly 10 times
that of residents in United States, a
finding markedly different from the
experience of the PUVA cohort re-
ported here (Stern, 1999). A compar-
ison of our data and population-based
data from Australia provides a context
for informing clinicians and advising
patients about the long-term risk of
BCC with PUVA, particularly for those
exposed when young.
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TO THE EDITOR
As a biostatistician, I read the article by
Lu et al. (2008) with concern. I wish to
raise several issues, some echoed by
other commentators (Ellefson, 2009;
Staeb et al., 2009).
ISSUE 1
I have questions about the design of
the study. Was randomization used
to select treatment groups? If so,
it is important that randomization
was carried out at the end—not
the beginning—of the pre-treatment
period. If mice were separated into
groups before this time, it is possible
that this part of the experiment
induced differences before treatment
application.
Table 2. Anatomic distribution and incidence of BCCs in PUVA cohort
1990–1999 and Queensland (Australia) 1997–2006
PUVA cohort Australia1
Anatomical site
No. of tumors
(%) Incidence rate2 No. of tumors (%) Incidence rate2
Head and neck 488 (51) 122 379 (57) 29
Trunk 284 (30) 71 111 (17) 9
Upper extremities 77 (8) 19 118 (18) 9
Lower extremities3 108 (11) 27 54 (8) 4
All sites 959 239 662 51
BCC, basal cell cancer; PUVA, psoralens plus UVA.
1Richmond-Sinclair et al. (2008).
2BCCs per 1,000 person-years.
3Includes buttocks and hip.
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